The importance and challenges of developing a pharmacogenetics test for hypertension

Pharmacogenomics. 2019 Jun;20(8):563-566. doi: 10.2217/pgs-2019-0056. Epub 2019 May 28.

Authors

Eric M Snyder¹, Eli F Kelley², Ryan Sprissler^{1

3}, Thomas P Olson^{1

4}

Affiliations

¹ Geneticure, Inc., Rochester, MN 55902, USA.
² School of Kinesiology, University of Minnesota, Minneapolis, MN 55455, USA.
³ University of Arizona Genomics Core, Tucson, Arizona, AZ 85721 USA.
⁴ Division of Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.

PMID: 31136254
DOI: 10.2217/pgs-2019-0056

No abstract available

Keywords: hypertension; personalized medicine; pharmacogenetics.

Publication types

Editorial

MeSH terms

Cytochrome P-450 CYP2D6 / genetics
Genome-Wide Association Study
Humans
Hypertension / drug therapy*
Hypertension / genetics
Pharmacogenetics*
Precision Medicine*
Receptors, Adrenergic, beta-1 / genetics

Substances

ADRB1 protein, human
Receptors, Adrenergic, beta-1
Cytochrome P-450 CYP2D6